/KNSA
KNSA Stock - Kiniksa Pharmaceuticals, Ltd.
Healthcare|BiotechnologyNASDAQ
$43.19+2.83%
+$1.19 (+2.83%) • Dec 19
81
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.95
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).79
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+14.6%upside
Target: $49.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KNSA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$42.76 – $43.62
TARGET (TP)$49.50
STOP LOSS$39.73
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.01
52W High$43.73
52W Low$17.82
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $423.24M | $270.26M | $220.18M | $38.54M | N/A |
| Gross Profit | $362.33M | $213.74M | $197.28M | $29.44M | $-3,805,000 |
| Gross Margin | 85.6% | 79.1% | 89.6% | 76.4% | N/A |
| Operating Income | $-45,616,000 | $-25,196,000 | $9.77M | $-156,636,000 | $-157,363,000 |
| Net Income | $-43,193,000 | $14.08M | $183.36M | $-157,924,000 | $-161,381,000 |
| Net Margin | -10.2% | 5.2% | 83.3% | -409.7% | N/A |
| EPS | $-0.60 | $0.20 | $2.64 | $-2.30 | $-2.61 |
Company Overview
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$44
Average Target
↑ 0.7% Upside
Now
$34
Low
$44
Average
$60
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 29th 2025 | TD Cowen | Initiation | Buy | $60 |
| March 13th 2025 | Citigroup | Initiation | Buy | $40 |
| September 13th 2024 | Jefferies | Initiation | Buy | $40 |
| May 3rd 2024 | Wells Fargo | Initiation | Overweight | $34 |
Earnings History & Surprises
KNSABeat Rate
63%
Last 19 quarters
Avg Surprise
+7.4%
EPS vs Estimate
Beats / Misses
12/6
1 met exactly
Latest EPS
$0.23
Q4 2025
EPS Surprise History
Q1 24
+136.4%
$0.04vs$-0.11
Q2 24
-78.6%
$-0.25vs$-0.14
Q3 24
+33.3%
$-0.06vs$-0.09
Q4 24
-662.4%
$-0.18vs$-0.02
Q1 25
-100.0%
$-0.12vs$-0.06
Q2 25
+450.0%
$0.11vs$0.02
Q3 25
+27.8%
$0.23vs$0.18
Q4 25
-30.3%
$0.23vs$0.33
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 24, 2026 | $0.37 | — | — | — |
Q4 2025 | Oct 28, 2025 | $0.33 | $0.23 | -30.3% | ✗ MISS |
Q3 2025 | Jul 29, 2025 | $0.18 | $0.23 | +27.8% | ✓ BEAT |
Q2 2025 | Apr 29, 2025 | $0.02 | $0.11 | +450.0% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $-0.06 | $-0.12 | -100.0% | ✗ MISS |
Q4 2024 | Oct 29, 2024 | $-0.02 | $-0.18 | -662.4% | ✗ MISS |
Q3 2024 | Jul 23, 2024 | $-0.09 | $-0.06 | +33.3% | ✓ BEAT |
Q2 2024 | Apr 23, 2024 | $-0.14 | $-0.25 | -78.6% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-0.11 | $0.04 | +136.4% | ✓ BEAT |
Q4 2023 | Oct 31, 2023 | $-0.18 | $-0.20 | -11.1% | ✗ MISS |
Q3 2023 | Jul 25, 2023 | $-0.16 | $-0.02 | +87.5% | ✓ BEAT |
Q2 2023 | May 2, 2023 | $-0.18 | $-0.18 | 0.0% | = MET |
Q1 2023 | Feb 28, 2023 | $-0.23 | $0.06 | +126.1% | ✓ BEAT |
Q4 2022 | Nov 1, 2022 | $0.38 | $0.67 | +76.3% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.43 | $-0.29 | +32.6% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $-0.52 | $-0.36 | +30.8% | ✓ BEAT |
Q1 2022 | Feb 22, 2022 | $-0.44 | $-0.53 | -20.5% | ✗ MISS |
Q4 2021 | Nov 1, 2021 | $-0.63 | $-0.44 | +30.2% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $-0.69 | $-0.61 | +11.6% | ✓ BEAT |
Q2 2021 | May 4, 2021 | $-0.73 | $-0.72 | +1.4% | ✓ BEAT |
Latest News
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $55
📈 PositiveBenzinga•Oct 29, 2025, 06:09 PM
Kiniksa Expects 2025 Arcalyst Net Product Revenue Of $670M-$675M Compared To Prior Guidance Of $625M-$640M
📈 PositiveBenzinga•Oct 28, 2025, 11:43 AM
Kiniksa Pharmaceuticals Q3 2025 EPS $0.23 Misses $0.26 Estimate, Sales $180.855M Beat $167.358M Estimate
➖ NeutralBenzinga•Oct 28, 2025, 11:34 AM
Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $50
📈 PositiveBenzinga•Oct 17, 2025, 03:23 PM•Also:
Kiniksa Pharmaceuticals Announces FDA Grants Orphan Drug Designation For KPL-387 For Pericarditis
📈 PositiveBenzinga•Oct 17, 2025, 12:06 PM
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $44
📈 PositiveBenzinga•Oct 13, 2025, 01:03 PM
TD Cowen Initiates Coverage On Kiniksa Pharmaceuticals with Buy Rating, Announces Price Target of $60
📈 PositiveBenzinga•Sep 29, 2025, 02:19 PM
Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $45
📈 PositiveBenzinga•Sep 25, 2025, 01:36 PM
Frequently Asked Questions about KNSA
What is KNSA's current stock price?
Kiniksa Pharmaceuticals, Ltd. (KNSA) is currently trading at $43.19 per share. The stock has moved +2.83% today.
What is the analyst price target for KNSA?
The average analyst price target for KNSA is $49.50, based on 1 analyst.
What sector is Kiniksa Pharmaceuticals, Ltd. in?
Kiniksa Pharmaceuticals, Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KNSA's market cap?
Kiniksa Pharmaceuticals, Ltd. has a market capitalization of $3.17 billion, making it a mid-cap company.
Does KNSA pay dividends?
No, Kiniksa Pharmaceuticals, Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADPT
Adaptive Biotechnologies Corporation
$17.00
Mkt Cap: $2.6B
APLS
Apellis Pharmaceuticals, Inc.
$24.65
Mkt Cap: $3.1B
CDTX
Cidara Therapeutics, Inc.
$220.80
Mkt Cap: $5.6B
CPRX
Catalyst Pharmaceuticals, Inc.
$23.74
Mkt Cap: $2.9B
FOLD
Amicus Therapeutics, Inc.
$14.18
Mkt Cap: $4.4B
IDYA
IDEAYA Biosciences, Inc.
$33.55
Mkt Cap: $2.9B
MLYS
Mineralys Therapeutics, Inc.
$36.83
Mkt Cap: $2.4B
SRRK
Scholar Rock Holding Corporation
$43.90
Mkt Cap: $4.5B
VCYT
Veracyte, Inc.
$42.92
Mkt Cap: $3.4B
ZLAB
Zai Lab Limited
$18.04
Mkt Cap: $2.0B
Explore stocks similar to KNSA for comparison